IL23R and ulcerative colitis: Variants in IL‐23R and NOD2 strongly influence IBD susceptibility, and recent work has highlighted how targeting the IL‐23/Th17 axis can translate these findings into effective biologic therapies in CD and ulcerative colitis [35, 36].